Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.

Cho YK, Sung H, Lee HJ, Joo CH, Cho GJ.

Int Immunopharmacol. 2001 Jul;1(7):1295-1305.

PMID:
11460310
2.

High frequency of grossly deleted nef genes in HIV-1 infected long-term slow progressors treated with Korean red ginseng.

Cho YK, Lim JY, Jung YS, Oh SK, Lee HJ, Sung H.

Curr HIV Res. 2006 Oct;4(4):447-57.

PMID:
17073619
3.

Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.

Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.

AIDS. 1996 Jun;10(6):625-33.

PMID:
8780817
4.

Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.

Leriche-Guérin K, Trabaud MA, Cotte L, Bissuel F, Deruelle E, Rougier P, Trépo C.

Eur J Clin Microbiol Infect Dis. 1997 Sep;16(9):660-8.

PMID:
9352259
5.

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.

Kelleher AD, Roggensack M, Jaramillo AB, Smith DE, Walker A, Gow I, McMurchie M, Harris J, Patou G, Cooper DA.

AIDS. 1998 Jan 22;12(2):175-82.

PMID:
9468366
7.
8.

A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.

Gatell JM, Leal M, Mallolas J, Vidal C, Pumarola T, Parra R, Padró S, Caruz A, Falgueras T, Rey C, Sánchez-Quijano A, Torres Y, Lissen E, Jiménez de Anta MT, Soriano E.

Antivir Ther. 1996 Apr;1(2):105-12.

PMID:
11321180
9.

HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, Lockman S, Fowler MG, Hanson C, Landesman S, Moye J, Rich KC, Zorrilla C, Japour AJ.

AIDS. 2000 Feb 18;14(3):263-71.

PMID:
10716502
10.
11.

Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.

Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.

Antivir Ther. 1996 Dec;1(4):211-9.

PMID:
11324823
12.

Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.

Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC.

J Virol Methods. 1993 Mar;41(3):297-310.

PMID:
8097199
13.

Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.

Cleland A, Watson HG, Robertson P, Ludlam CA, Brown AJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 May 1;12(1):6-18.

PMID:
8624762
14.
15.
16.
17.

Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.

Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):330-4.

PMID:
7533640
18.

Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.

Magierowska-Jung M, Agut H, Katlama C, Autran B, Huraux JM.

J Med Virol. 1997 Jan;51(1):48-55.

PMID:
8986949
19.

Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.

Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R.

Antiviral Res. 1993 Apr;20(4):267-77.

PMID:
8097906
20.

Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.

Kamkamidze G, Sullivan T, Charbonneau T.

J Clin Virol. 2001 Aug;22(1):143-8.

PMID:
11418362

Supplemental Content

Support Center